Subclassification of Type 2 Diabetes

The objective of the CCG is to characterize pathogenetic mechanisms in prediabetic at-risk subjects and biomarkers indicating progression to overt type 2 diabetes in these individuals. We will analyse metabolomic, proteomic and genetic marker profiles together with bioimaging (MRI/MRS) and metabolic tests to provide new insights into the pathways involved in the development of type 2 diabetes. As this is a heterogeneous disease in its clinical appearance, we also hypothesize that distinct pathogenic mechanisms lead to different subtypes of type 2 diabetes and that knowledge of these entities will allow individualized risk prediction and prevention.

We use cookies to improve your experience on our Website. We need cookies to continually improve our services, enable certain features, and when we embed third-party services or content, such as the Vimeo video player or Twitter feeds. In such cases, information may also be transferred to third parties. By using our website, you agree to the use of cookies. We use different types of cookies. You can personalize your cookie settings here:

Show detail settings
Please find more information in our privacy statement.

There you may also change your settings later.